Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India that was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer; he named the company after his two sons. The company initially sold its products in India, Russia, and Africa. The company went public in India in 1999, and used some of the proceeds to build its first research facility. Saldanha's son Glenn took over as CEO in 2001, having returned to India after working at PricewaterhouseCoopers. By 2008 Glenmark was the fifth-biggest pharmaceutical company in India.[1]Finally A Good News In 2020 Fight Against Pandemic COVID19 Company Launched Under Brand Name FabiFlu.

Glenmark Pharmaceuticals
Public company
IndustryPharmaceuticals
Founded1977
FoundersGracias Saldanha
Headquarters
Mumbai
,
India
Area served
Global
Key people
Glenn Saldanha, MD & Chairman
ProductsMedicines and vaccines
Websiteglenmarkpharma.com

By 2011 the founder of the company was one of the richest men in India,[2] and Glenmark had worldwide sales of $778 million, a 37% increase over the last year's sales; the growth was driven by Glenmark's entry into the US and European generics markets.[3]

In the mid-2010s the generics industry in general began transitioning to the end of an era of giant patent cliffs in the pharmaceutical industry; patented drugs with sales of around $28 billion were set to come off patent in 2018, but in 2019 only about $10 billion in revenue was set to open for competition, and less the next year. Companies in the industry responded with consolidation or trying to generate new, patented drugs.[4]

Glenn Saldanha took the company down the path of seeking innovation, which was controversial within the company and with shareholders.[4] The company focused on new drugs[5] and biosimilars in the fields of cancer, dermatology and respiratory diseases, which it sought to monetize by partnering with major pharmaceutical companies.[4][6] In 2016 it had four such drugs in clinical trials.[7] For the financial year 2016–2017 its sales were around 81 billion INR (ca. $1.25 billion), making it the fourth-biggest Indian pharmaceutical company.[8]

In May 2019, Yasir Rawjee was elected as CEO of Glenmark Life Sciences.[9]

Notes and references
  1. Hiscock, Geoff (2008). India's Global Wealth Club: The Stunning Rise of Its Billionaires and Their Secrets of Success. John Wiley & Sons. pp. 65–66. ISBN 9780470822388.
  2. "India's Richest: #69 Gracias Saldanha". Forbes. 2011.
  3. Levin, Jennifer. "5. Glenmark Pharmaceuticals". FiercePharma.
  4. Altstedter, Ari (18 May 2017). "Glenmark's Glenn Saldanha seeks a new holy grail as generic drugs run dry". Live Mint.
  5. Business, Today (11 July 2019). "Glenmark, Torrent Pharma ink pact to co-market diabetes drug in India". Retrieved 20 July 2019.
  6. Trivedi, Isha (22 December 2016). "We plan to out-license our entire novel drugs pipeline: Glenmark CMD". Live Mint.
  7. Altstedter, Ari (15 July 2016). "Glenmark Expects Cash Surge From License Deals in Next 18 Months". Bloomberg.com.
  8. Ninov, Georgi (17 May 2017). "India Pharmaceutical Sector – Small Growth in Sales during FY 2016-17". CEICdata.
  9. "Glenmark appoints Yasir Rawjee as CEO of Glenmark Life Sciences". Medical Dialogues. 8 May 2019.
  10. "Glenmark gets FDA nod of company's first NDA for Ryaltris". Biospectrum. 8 August 2018. Retrieved 20 July 2019.
  11. Reuters (21 May 2018). "Glenmark Pharmaceuticals Submitts NDA To U.S. FDA For Ryaltris". Reuters. Retrieved 20 July 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.